Interplay between two hormone-independent activation domains in the androgen receptor

Cancer Research

Volumn 66, Issue 1, 2006, Pages 543-553

  Callewaert, Leen ^a   Van Tilborgh, Nora ^a   Claessens, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ARGININE; LYSINE; PROTEIN P160; TAU PROTEIN; TAU PROTEIN 1; TAU PROTEIN 2; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN COS7; CHO CELL; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; RECEPTOR INTRINSIC ACTIVITY; TRANSACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL LINEAGE; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 31544451068     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2389     Document Type: Article

References (37)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Foley R, Hollywood D, Lawler M. Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 2004;11:477-88.
3. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
4. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-76.
5. Tindall D, Horne FM, Hruszkewycz A, et al. Symposium on androgen action in prostate cancer. Cancer Res 2004;64:7178-80.
6. Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J Cell Sci 2003;116:585-6.
7. Han G, Foster BA, Mistry S, et al. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001;276:11204-13.
8. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997;387:733-6.
9. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 1999;19:6085-97.
10. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-92.
11. Christiaens V, Bevan CL, Callewaert L, et al. Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. J Biol Chem 2002;277: 49230-7.
12. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000;9:267-74.
13. Ikonen T, Palvimo JJ, Jänne OA. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 1997;272:29821-8.
14. Steketee K, Berrevoets CA, Dubbink HJ, et al. Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. Eur J Biochem 2002;269:5780-91.
15. Callewaert L, Verrijdt G, Christiaens V, Haelens A, Claessens F. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J Biol Chem 2003;278:8212-8.
16. He B, Gampe RT, Jr, Kole AJ, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004;16:425-38.
17. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002;16:647-60.
18. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995;270:7341-6.
19. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2;277-85.
20. Haelens A, Verrijdt G, Callewaert L, et al. DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation. Biochem J 2003;369:141-51.
21. Verrijdt G, Haelens A, Schoenmakers E, Rombauts W, Claessens F. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J 2002;361:97-103.
22. Verrijdt G, Schoenmakers E, Haelens A, et al. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 2000;275: 12298-305.
23. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266: 510-8.
24. Palvimo JJ, Kallio PJ, Ikonen T, Mehto M, Jänne OA. Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Mol Endocrinol 1993;7: 1399-407.
25. Dahlman-Wright K, Almlof T, McEwan IJ, Gustafsson JA, Wright AP. Delineation of a small region within the major transactivation domain of the human glucocorticoid receptor that mediates transactivation of gene expression. Proc Natl Acad Sci U S A 1994;91:1619-23.
26. Wärnmark A, Gustafsson JA, Wright AP. Architectural principles for the structure and function of the glucocorticoid receptor tau 1 core activation domain. J Biol Chem 2000;275:15014-8.
27. Chamberlain NU Whitacre DC, Miesfeld RL. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. J Biol Chem 1996;271:26772-8.
28. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions. J Biol Chem 2002;277: 20079-86.
29. Callewaert L, Verrijdt G, Haelens A, Claessens F. Differential effect of small ubiquitin-like modifier [SUMO]-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. Mol Endocrinol 2004;18:1438-49.
30. Metivier R, Petit FG, Valotaire Y, Pakdel F. Function of N-terminal transactivation domain of the estrogen receptor requires a potential α-helical structure and is negatively regulated by the A domain. Mol Endocrinol 2000;14:1849-71.
31. Tung L, Shen T, Abel MG, et al. Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity. J Biol Chem 2002;276: 39843-51.
32. Han G, Buchanan G, Ittmann M, et al Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 2005;102:1151-6.
33. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 [transcriptional intermediary factor2]. Mol Endocrinol 1998;12:1172-83.
34. McEwan IJ. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer 2004; 11:281-93.
35. Claessens F, Verrijdt G, Schoenmakers E, et al. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 2001;76:23-30.
36. Chang CY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26:225-8.
37. Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl- terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998;273:92-101.